- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.
1 report, 1 independent
Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Merck KGaA
German multinational science and technology company
-
Food and Drug Administration
government organization in Nonthaburi, Thailand
-
Vertex Pharmaceuticals
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- BioPharma DiveVertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free d